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Transcription Through Chromatin – Link to
Diseases and Therapeutics
Hari Kishore A, Sushma S Iyengar and  Tapas K Kundu
The expression of chromosomal genes is regulated by post-
translational modification of both histone and nonhistone
chromatin proteins and ATP-dependent remodeling of chro-
matin. Dysfunction of the modification and remodeling
machineries can lead to several diseases, which include
cancer, cardiac hypertrophy, and asthma. Many genetic
diseases can also lead to malfunction of the machinery. The
enzymes responsible for chromatin organization are the
new targets for therapeutics. Inhibitors and activators of
histone acetyltransferases and inhibitors of histone
deacetylases may serve as new generation drugs.
Introduction
Chromatin is the highly organized and dynamic nucleoprotein
form of the genome that facilitates genes to be turned on and off
depending upon the cellular requirements in a very precise
manner. In agreement with the number of functional genes, a
major part of the genome is transcriptionally inert and is present
as heterochromatin1 whereas, active genes are located in euchro-
matin2. In the active chromatin, core histone tails are dyna-
mically modified by histone acetytransferases, deacetylases,
methyltransferases and kinases. Histone acetyltransferases acety-
late specific lysine residues of histone H3 (K14 and K10) and
histone H4 (K8 and K16) for transcriptional activation. These
acetylated residues are deacetylated by specific histone
deacetylases when the genes need to be silenced. The active
genes are methylated at the K4 site of histone H3 with func-
tional consequences. Interestingly, no demethylase is known so
far. However, methylation of histone H3 at K9 position re-
presses transcriptional activity. Presumably, activation and re-
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pression by methylation are regulated by the displacement of
methylated histones. Phosphorylation of the histone H3 (at Ser
10) has been shown to be important for transcriptional activa-
tion. Furthermore, active gene promoters were found to be
devoid of histone H1 and the CpG3 islands at the promoter are
not methylated. ATP-dependent chromatin remodeling ma-
chinery facilitates to achieve both active and repressed state of
chromatin by altering the pathway of DNA over the nucleoso-
mal core. There are several ATP-dependent chromatin remodel-
ing complexes, which get recruited on the chromatin by differ-
ent activators and repressors to perform their specific role.
However, chromatin is not only the complex of histone and
DNA, several nonhistone chromatin-associated proteins are also
integral parts of chromatin. Posttranslational modifications (e.g.,
acetylation/deacetylation/phosphorylation) of nonhistone pro-
teins regulate their dynamic association with chromatin and the
consequent function. Dysfunction of any of these machineries
leads to one or several diseases in humans. Thus, these are the
newly identified therapeutic targets. In this article we will dis-
cuss how the mutation or altered function of histone acetyl-
transferases, histone deacetylases, histone methyltransferases
and some of the components of ATP-dependent remodeling
cause different diseases. We will also briefly highlight the present
status of new therapeutic agents targeted to histone acetyltrans-
ferases and histone deacetylases.
Histone Acetyl Transferases (HATs) and Diseases
Acetylation of histones is a reversible process. The balance
between acetylation and deacetylation is one of the key factors
for the regulation of gene expression. Hyperacetylation of his-
tones associated with normally silenced genes or deacetylation
of histones associated with actively transcribed genes may lead
to several disorders. Acetylation-associated disorders may occur
through i) hyperacetylation and derepression of normally re-
pressed promoters; ii) the hypoacetylation and repression of
genes necessary for cell viability, and iii) mistargeting of HAT
and HDAC activity.
Keywords.
Cancer, chromatin therapy, car-
diac hypertrophy, HIV, Rubin-
stein–Taybi syndrome.
1 Heterochromatin comprises of
densely staining condensed
chromosomal regions, believed
to be for the most part, geneti-
cally inert. chromatin that re-
mains tightly coiled throughout
the cell cycle.
2 Euchromatin is the  chromo-
somal region that stains poorly
or not at all; thought to contain
the normally functioning genes.
Region of eukaryotic chromo-
some that is diffuse during in-
terphase. Presumably the ac-
tively transcribing DNA of the
chromosomes.
3 CpG stands for cytosine and
guanine separated by a phos-
phate which links the two nucle-
otides together in DNA. Unlike
CpG sites in the coding region
of a gene, the CpG sites in the
CpG islands are un-methylated.
This raises the possibility that
methylation of CpG may inhibit
the expression of a gene by al-
tering the promoter. CpG is-
lands are often located around
the promoters of housekeep-
ing genes (which are essential
for general cell functions) or
o ther  genes f requent ly  ex-
pressed in a cell.
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Mutation, mistargeting and translocation4 (formation of fusion
proteins) of the histone acetyltransferases cause aberrant acety-
lation.
Mutation in HATs
Rubinstein–Taybi Syndrome  (RTS) is a developmental haplo-
insufficiency5 disorder, which is marked by mental retardation,
craniofacial defects, broad big toes and thumb. These patients
are highly susceptible to cancer. Mutation in the cbp locus results
in RTS. It was found that a single mutation at the plant homeodo-
main (PHD)-type zinc finger in the HAT domain of cbp causes
this syndrome. The mutation alters a conserved finger amino
acid residue E to K at position 1278. Interestingly, this mutation
in cbp also abolishes its histone acetyltransferase activity.
Mistargeting of HATs – Sequestration and Degradation Mani-
fested in Neurodegenerative Disease.
Spinal and Bulbar Muscular Atrophy (SBMA): Spinal and
bulbar muscular atrophy is an inherited neurodegenerative dis-
ease caused by CAG repeat expansion in the androgen receptor
gene. This results in an expanded polyglutamine tract, which
confers a novel, toxic function to the affected protein. The
transcriptional activator CBP (Cyclic AMP Response Element
Binding Protein) is incorporated into nuclear inclusion bodies
formed by polyglutamine-containing proteins. Free CBP levels
are reduced in cells expressing expanded polyglutamine, though
the CBP mRNA level is not affected. Over expression of CBP can
rescue cells from polyglutamine-mediated toxicity.
Huntington’s Disease: This disease is a fatal neurodegenerative
disease with a late onset and is inherited in a dominant fashion.
It is also associated with increase in the length of a CAG triplet
repeat present in the huntingtin gene located on chromosome
4p16.3. Mutant huntingtin protein from human brain cells is
more resistant to proteolysis than normal huntingtin, which
leads to aggregation and toxicity through the sequestration of
important targets, including normal huntingtin protein.
4 Translocations are chromo-
somal abnormalities which oc-
cur when chromosomes break
and the fragments rejoin to
other chromosomes.
5 Haploinsufficiency is the situ-
ation in which an individual who
is heterozygous for a certain
gene mutation or hemizygous
at a particular locus, often due
to a deletion of the correspond-
ing allele, is clinically affected
because a single copy of the
normal gene is incapable of
providing sufficient protein pro-
duction as to assure normal
function.
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Polyglutamine-containing domain of huntingtin directly binds
the acetyltransferase domains of CBP and PCAF (p300-CBP
Associated Factor) and precipitate them from the cellular envi-
ronment. The PolyQ-huntingtin also inhibits acetyltransferase
activity of  p300, CBP and PCAF in vitro (Figure 1).
Translocations of HATs
MOZ (Monocytic leukemia Zinc finger) gene fusions:  MOZ-
CBP fusion protein is expressed due to a translocation [t(8;16)
(p11;p13)] in Acute Myeloid leukemia (AML). This fusion
protein may be mistargeted or misregulated which leads to
altered chromatin acetylation leading to either hyperacetylation
of nonspecific gene targets or hypoacetylation in case of
mistargeting or loss of function (Figure 2 A and B).
MLL (Mixed Lineage Leukemia) gene fusions: MLL-CBP fu-
sion protein is expressed in translocation [t(11;16)(q23;p13)] in
case of therapy-related AML, myelodysplastic syndrome, or
chronic myelomonocytic leukemia. MLL is a homolog of the
Drosophila trithorax (trx) gene involved in proper homeotic gene
expression and regulation of chromatin structure. MLL marks
CBP sequestration
Huntingtingene
CAG repeats
Poly Glutamine-Huntingtinprotein
CBP
Loss of 
function
Degradation
Histone
Acetylation/
coactivator
Caspases
Figure 1. Due to the intro-
duction of CAG repeats in
huntingtin gene, a PolyQ-
huntingtin protein is ex-
pressed which sequesters
normal Hunt-ingtin and
CBP. This CBP forms inclu-
sion bodies, which are fur-
ther degraded by caspa-
ses6.
6 Caspase is a protein that is
involved in apoptosis (Box 1).
Caspases are characterized by
their unusual ability to cleave
proteins at specific sites. Active
caspases can often activate
other caspases, leading to a
cascade of protein degrada-
tion.
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Figure 2. Aberrant gene expression by the HAT containing fusion proteins due to chromosomal
translocations. (A) During the normal course of gene expression MOZ/MLL interacts with specific
proteins and get recruited to the promoter in response to stimuli. p300/CBP  interacts with promoter
bound gene specific activator and activates the transcription. (B) In cancerous condition translo-
cation derived fusion proteins are expressed (MOZ-CBP, MOZ-TIF2, MLL-CBP or MLL-p300). These
fusion proteins may (I) be mistargeted to a non-specific gene; (II) misregulate a specific target gene
(hyper-activation); (III) lose function resulting in inactivation of gene.
(A)
(B)
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the boundaries of transcriptional activity by discriminating
among DNA methylation states. The fusion protein has A/T
hooks and cysteine-rich DNA recognition domain of MLL
fused to intact CBP, and it lacks C-terminal SET domain, which
is highly conserved in several chromatin-associated proteins.
The SET domain of MLL is very important for interacting with
hSNF5 (component of SWI/SNF, a chromatin-remodeling com-
plex), which has a direct effect on the transcription. Thus the
fusion protein MLL-CBP fails to recruit SWI/SNF to its target.
MORF gene fusions: MORF-CBP fusion proteins are expressed
in [t(10;16)(q22;p13)] in childhood AML. MORF belongs to
MYST family of HATs. The MORF-CBP protein retains the
zinc fingers, two nuclear localization signals, the HAT domain,
a portion of the acidic domain of MORF and the CBP. CBP
retains CREB-binding domain, three Cys/His-rich regions,
bromodomain, HAT domain and the Glu-rich domains. The
functional implications of this fusion protein are yet to be eluci-
dated.
Abbreviations
Bad – Bcl2-antagonist of cell death protein
BRCA1 – Breast Cancer 1
CIP1 – CDK-Interacting Protein 1
CNSL – Cashew Nut Shell Liquid
CTPB – [N-(4-chloro-3-trifluoromethyl-phenyl)-
2- ethoxy-6-pentadecyl-benzamide]
ETO – eight-twenty-one (a zinc finger nuclear
protein)
FMR1 – Fragile-X Mental Retardation 1
MORF – MOZ-related Factor
MTG16 – myeloid transforming gene chromosome
16
PLZF – promyelocytic leukemia zinc finger
PML – promyelocytic leukemia
RSK2 – p90 ribosomal S6 protein kinase 2
SMYD3 – SET and MYND containing 3
WAF1 – Wildtype p53 – Activated Fragment 1
For other abbreviations see [1].
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Histone Deacetylases (HDACs) and Diseases
Three classes (I, II and III) of  HDACs, function in a closely
coordinated and  targeted manner to direct the deacetylation of
histones of a gene to be repressed. Transcriptional repressors
like YY1, Mad/Max, and NCoR/Smrt form complexes with
HDACs. HDACs along with Mad/Max and RB (cell cycle regu-
lators) form a multi-subunit repressor complex, which represses
gene expression in a targeted manner. This repressor complex
can be disrupted by over expression of c-Myc or v-Ski which
induces cell-cycle progression and transformation. RB associ-
ates with transcription factor E2F which represses E2F-depen-
dent genes and regulates S-phase entry in cell cycle. This repres-
sion is brought about by interaction of RB with HDACs. Muta-
tions in RB disrupts RB-HDAC complex which triggers uncon-
trolled cell proliferation. HDACs are associated with NURD
complex, which has helicase/ATPase activity and specifically
binds to methylated DNA. HDACs also associate with MeCP27.
MeCP2 binds to methylated DNA and the associated HDAC
deacetylates the chromatin to silence the gene. Thus HDACs
have a role in chromatin remodeling and promoter silencing. In
various tumors, promoters of RB, p15ink4b, and p16ink4a were
found to be hypermethylated, as a result these genes are silenced.
Presumably, HDACs are also involved to repress these genes.
Protein Fusions Involving HDACs
RARa/PML and RARa/PLZF in Acute Promyelocytic Leuke-
mia (APL): RARa (Retinoic Acid Receptor8) represses tran-
scription by HDAC recruitment. Retinoic acid disrupts this
complex and activates retinoic acid-inducible genes. In case of
fusion proteins like RARa/PML  (ProMyelocytic Leukemia)
and RARa/PLZF (Promyelocytic Leukaemia Zinc Finger) the
repressor complex in association with HDAC becomes insensi-
tive to RA. Thus the RA-responsive genes remain repressed and
lead to blockage of hematopoietic differentiation.
AML-fusions: In leukemia, HDAC-mediated repression blocks
8 Retinoic Acid Receptor (RAR):
Retinoic Acid receptors (RARs)
are nuclear receptors related
to the steroid and thyroid hor-
mone receptors, a family of pro-
teins that function as ligand-
dependent transcription fac-
tors. Several RAR isoforms have
been identified in mammals -
RAR-alpha, -beta and -gamma
as well as novel nuclear recep-
tors known as RXR (Retinoid X
receptor), which are distantly
related to RARs and respond to
h igh concent ra t ions  o f  RA.
Nuclear receptors act as tran-
scription factors by binding to
specific DNA recognition se-
quences generally located up-
stream of responsive genes.
Although RARs can act ivate
gene expression through bind-
ing to thyroid hormone respo-
nse elements, a much more
specif ic and potent Retinoic
acid response element (RARE)
has been identif ied recently
within the promoter of the RAR-
beta gene.
7 Methyl CpG binding Protein
(MeCP2): The MeCP2 protein
binds to DNA at regions called
CpG islands, which frequently
occur near the beginning of a
gene. The protein then inter-
acts with other proteins to form
a complex that turns off the
gene.
30 RESONANCE ç November   2004
GENERAL  ç ARTICLE
‘myeloid differentiation’ 9. It has been found that in these pa-
tients AML-1 is present as fusion protein with ETO, MTG16
and TEL. Due to the formation of fusion proteins (DNA bind-
ing domain of AML-1 and ETO, MTG16 and TEL) HDAC-
association mediated repression becomes irreversible, which
blocks myeloid differentiation.
Methylation of Histones and Diseases
In the past two years, studies on histone methylation have
gained immense importance and that has lead to several discov-
eries. Unlike histone acetylation, the reverse step of methylation
is not known yet. Thus, methylation is a sort of permanent mark
on the genome. Methylation may activate as well as repress
chromatin, based on the position of lysine and arginine residues
in different histones (predominantly H3 and H4). Significantly,
both methylation-dependent activation and repression of chro-
matin, function in a highly organized manner along with acety-
lation and deacetylation. Dysfunction of methyl-transferases
thus may lead to several diseases. Many HMTases (Histone
methyl transtase) contain the SET domain. The SET domain
containing HMTase RIZ1 acts as tumor suppressor, suggesting
its function in cancer regulation. The other important example
is MLL, which is an HMTase that can be converted into
oncoprotein by acquisition of transcription activation domain
of EEN. Most recently, a novel HMTase, SMYD3, has been
discovered. It has been found that SMYD3 is over expressed in
majority of colorectal and hepatocellular carcinomas. It is also a
SET domain containing HMTase, which specifically methylates
H3-K4. The silencing of the SMYD3 by siRNA in cancer cells
resulted in significant growth suppression. Another genetic
disease, Fragile X syndrome is caused by an expansion of a poly-
morphic CAG triplet repeat that results in silencing of FMR1
gene present on the X-chromosome. This is characterized by
hypermethylation of CpG island in the FMR1 gene promoter
and deacetylation of histone H3 and H4. In fragile X cells, there
is a decrease in methylation of histone H3-K4 with a large
increase in methylation at H3-K9. The high level of H3-K9
9  Myeloid differentiation: Dif-
ferent iat ion of  erythrocytes,
megakaryocytes, platelets, ba-
sophils, eosinophils, neutro-
phi ls,  monocytes, macroph-
ages, and osteoclasts from my-
eloid precursor cells. In acute
leukemia differentiation is dis-
turbed by mechanisms typically
involving some transcription
factors participating in control
of differentiation. Genetic ab-
errations result in a differentia-
tion block and clonal expan-
sion. As a consequence, nor-
mal  hematopoies is  is  sup-
pressed with life-threatening
coagulation and immunity dis-
orders.
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methylation hampers H3 to be acetylated even after treatment of
fragile X cells with HDACi, a treatment that fully restores acety-
lation of histone H4. This hereditary disorder is marked by
mental retardation.
Histone Kinases and Disease
Phosphorylation of histone H1 directs the compaction of chro-
matin whereas histone H3 phosphorylation leads to gene expres-
sion of c-jun, c-fos and c-myc. RSK2 , a histone, kinase is associ-
ated with Coffin–Lowry Syndrome (CLS), which is marked by
severe mental retardation, short stature, coarse facies, patulous
lips. Deletion, nonsense and missense mutations are observed in
patients with CLS. Western blot analysis of lymphoblastoid or
fibroblast cell lines derived from CLS patients could not detect
RSK2, which could be due to truncations. Sometimes though
the level of protein does not alter, the RSK2 phosphotransferase
activity of the mutant protein is impaired. RSK2 activates CREB
through phosphorylation (Ser-133), which is impaired in CLS.
RSK2 is also a part of the gene family implicated in cell cycle
regulation through MAPK pathway.
Modulators of Histone Modifying Enzymes as Thera-
peutics
HAT and HDAC Modulators as Therapeutics of the Future
A) HDAC inhibitors (HDACi): HDACs are important molecu-
lar targets for cancer therapy. Hence, HDACi gain importance
in the field of chemotherapy. HDAC inhibitors cause cell cycle
arrest, differentiation and/or apoptosis (Box 1) of many tumours,
suggesting their usefulness for chemotherapy and differentia-
tion therapy. Various classes of compounds (short-chain fatty
acids, hydroxamic acids, cyclic tetrapeptides, cyclic depsipeptides
and phenylene diamines) are known to be potent against HDAC
activity.  The first HDAC inhibitor was actually used as a ligand
attached to a solid support resin (affinity matrix) to purify
HDACs. Since then a number of HDAC inhibitors were
designed by modifying various naturally occurring molecules
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(Table 1). HDACi globally affect the repressive activities of
HDAC associated transcription factors and various chromatin
remodeling complex. HDACi exert growth inhibitory, pre-
apoptotic and differentiating activities in various cell lines irre-
spective of histological origin. Retinoic Acid induced differen-
tiation is enhanced by HDACi. Most of the HDACi upregulate
the expression of tumor suppressor proteins like p21WAF1/
Box 1. Apoptosis
Apoptosis, or programmed cell death, is a regulated physiological process leading to cell death character-
ized by cell shrinkage, membrane blebbing and DNA fragmentation. Failure of DNA damage repair
mechanism may also lead to apoptosis. Caspases, a family of cysteine proteases, are central regulators of
apoptosis. Once activated, these caspases cleave and activate downstream effector caspases, which in turn
cleave cytoskeletal and nuclear proteins and induce apoptosis. Too little or too much apoptosis plays a role
in many diseases. When there is misregulation of programmed cell death, the cells may become immortal
which leads to cancer or too many cells may get lysed as in the case of neurodegenerative diseases
(Alzheimer, Huntington, Parkinson).
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CIP1 (p21WAF1 a cyclin-dependent kinase inhibitor plays a
crucial role in G1/S and G2/M transitions of cell cycle). HDACi
also induce expression of CD86 possibly stimulating tumor
immunity.
There are considerable drawbacks and limitations of various
cancer drugs owing to which HDACi are gaining importance.
Most of the HDACi have multiple effects in addition to inhibi-
HDAC Inhibitors Properties
SAHA (Suberoylanilide Potent, cell-permeable inhibitor, induces differentiation in human
hydroxamic acid) breast cancer cells, induces apoptosis, displays anti-angiogenesis
activity by altering VEGF signaling in HUVECs.
Scriptaid Reversible medium-potency, hydroxamic acid-type, inhibits tumor
growth in vitro and in vivo and, in conjunction with AZA, acts to re-
express functional ER.
Suberoyl bis-hydroxamic acid Low-potency HDAC inhibitor, induces differentiation in murine
erythroleukemia cells.
Trichostatin A (TSA) Potent and reversible HDAC inhibitor, blocks cell cycle progression
at G1, it displays immunosuppressive activity in a mouse. Inhibits
angiogenesis. modulate CD4+ T-cell responses.
HC Toxin Potent, cell-permeable, cyclopeptide HDAC inhibitor, it displays
antineoplastic activity and up-regulates 15-lipoxygenase in colorectal
carcinoma cell lines.
Chlamydocin Naturally occurring cyclic tetrapeptide, increases the expression of
p21cip1/waf1, blocks cell cycle progression at G2/M phase of the cell
cycle, induces apoptosis by activating caspase-3, which in turn leads
to the cleavage of p21cip1/waf1.
Sodium butyrate Increases the expression levels of p21 (WAF-1) and inhibits G1-S
transition of the cell cycle. increases the expression of the Bad
protein, decreases Ca2+ release from intracellular stores
FK228 (depsipeptide) Potent inhibitor of HDAC1 and HDAC2.
Psammaplin A (PSMA) Physiologically stable marine natural product, induces the expression
of the cyclin dependent kinase inhibitor p21waf1
.
Sodium phenyl Butyrate A chemical chaperone, glutamine trap used as ammonia scavenger
(in patients with urea cycle disorder).
Valproic acid Considered for clinical trials for spinal muscular
 
atrophy
Sirtinol Inhibits yeast Sir2p transcriptional silencing activity in vivo, yeast
Sir2p and human SIRT2 deacetylase activity in vitro.
Table 1. Histone deace-
tylase inhibitors, potential
anticancer therapeutics.
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tion of deacetylase activity and cause toxicity to the cell. So the
search continues for stable, small molecular, cell-permeable,
non-toxic HDACi. Also an important factor to be considered is
the reversibility of action. Compounds like TSA, SAHA, sodium
phenyl barbiturate, depsipeptides either alone or in combina-
tion are proved to be successful in cancer therapy. Recently
compounds like arginine butyrate, cyclo (trp-trp) and cyclo
(phe-pro) have been shown to increase histone acetylation in
tumor derived cell lines.
Box 2.  Engineered Transcription Factors
Selective manipulation of specific gene expression can be a powerful tool in biomedicine. Typical
Transcription Factors (TFs) have DNA binding domain (DBD) and an effector (activation or repressor)
domain. By changing DBD and effector domains new TFs can be made which are gene specific. Among
DBDs, Zinc Finger Proteins (ZFPs) are widely studied. ZF are small DNA recognition motifs (30 amino
acids). A series of ZF can be designed to make a DBD specific for a particular gene. These are called Code-
based designed ZFs. ZFP TFs can be designed to upregulate or downregulate a particular target gene of
interest. These tailored ZFP TFs mimic natural transcriptional mechanism and thus provide an attractive
tool for regulating gene expression. A ZFP TF can be constructed by using DNA sequence of a promoter
of the specific target gene which forms a DBD to which a repression domain (e.g., Kruppel – associated
box A/B, v-erb or SID) or activation domain (e.g., p65 of NFkB or VP16) is linked.
ZFP TFs in Cancer therapy
Aberrant expression of genes can be detected from microarray analysis and protein profiling. This kind of
transcription profile is a diagnostic marker for cancer type and disease progression. By correcting this
abnormal expression of genes, disease condition can be corrected using engineered ZFP TFs. This is
referred to as ‘Transcription therapy’. These ZFP TFs can be delivered at a particular in vivo target using
adenovirus or retrovirus, fused to “delivery-short amino acid sequences”, directly injected into blood
stream. Also these ZFP TFs, can be controlled by linking a ligand-binding domain (e.g., steroid hormone
receptors, so that by administration of various doses of steroid hormone analogs gene expression can be
controlled).
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HDAC recruitment directed by DNA methylation as in the case
of Fragile X syndrome, has given clues to use of HDACi in
combination with DMTase (DNA methyltransferases) inhibi-
tors (5-aza-2'-deoxycytidine). This kind of combination therapy
restored methylation of DNA and acetylation of histones to
nearly wild type. Thus non-toxic, enzyme specific HDACi in
combination with other DMTase inhibitors could be very good
therapeutics for cancer in future. In the case of tumors harboring
fusion proteins like RARa-PML and RARa/PLZF there is
formation of an Retionic Acid-unresponsive complex with
HDAC. A combination of HDACi and RA has been proved to be
successful rather than RA alone as therapeutics. Most impor-
tantly HDACi arrest progressive neuronal degeneration induced
by polyglutamine repeat expansion. These findings raise the
possibility that therapy with HDACi may slow or prevent the
progressive neurodegeneration seen in Huntington’s disease.
Expression of huntingtin leads to hypo-acetylation of H3 and
H4, which is reversed by administration of HDACi.
HDAC of the host, inhibits HIV gene expression and virus
production and may contribute to latency of HIV within resting
CD4 T cells. HDACi are capable of inducing expression of
quiescent provirus, without fully activating cells or enhancing
de novo infection. Thus a combination of antiretroviral thera-
peutics and HDACi may in future help in treating AIDS.
B) HAT modulators: Although great progress has been made in
the study of HDACi, very little has been done in the area of
histone acetyltransferase modulators. Long before the discovery
of HATs, polyamine-CoA conjugates were found to inhibit the
histone acetyltransferase activity of cell extracts. The discovery
of different histone acetyltransferases made it possible to syn-
thesize more specific inhibitors of histone acetyltransferases.
Two synthetic inhibitors, Lysyl-CoA specific for p300 and H3-
CoA-20 targeted to PCAF were discovered recently. Both of
these inhibitors soon became useful tools to understand the
mechanism of p300 and PCAF function in vitro. However, cells
are impermeable to these inhibitors and being CoA conjugates,
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these are pharmacogenically poor. More recently, we have been
able to isolate two natural inhibitors from plant sources, which
permeate the cell and thus could be lead compounds for design-
ing drugs. These are anacardic acid, from CNSL and Garcinol
from Garcinia indica (Kokam) fruit rind. By using anacardic
acid, we have synthesized an amide derivative, CTPB, which
enhances the HAT activity of p300 specifically. To date CTPB is
the only known small molecular activator of any histone
acetyltransferase, which could be highly useful as an alternative
for HDACi. Also, CTPB could be used to disrupt the interaction
of p300 and PolyQ-Huntingtin and restore the normal levels of
histone acetyltransferase activity.
HMTase Inhibitors
Recently, an inhibitor AMI-1, specific to arginine methyltrans-
ferase activity, has been reported. It can inhibit the methyl-
transferase activity in vitro and in vivo. AMI-1 inhibits in vivo
arginine methylation of cellular proteins and can modulate
nuclear receptor regulated transcription from estrogen and an-
drogen receptor responsible elements. Therefore, it is effective
in inhibiting the action of certain hormones.
ATP-Dependent Remodeling Complexes and Diseases
Mutations in hSWI/SNF
SWI/SNF complex is an ATP-dependent chromatin remodeling
protein complex, which is composed of at least 11 different
proteins. It can either activate or repress transcriptional activity.
In rhabdoid tumours mutations (frameshift, nonsense and dele-
tion) have been reported in the hSNF5 gene. It is not clear how
these truncations affect SWI/SNF function. But these mutations
in malignancies show that SWI/SNF may contribute in regula-
tion of cell cycle. Inhibition of cell cycle could be achieved by
both activation and repression function of SWI/SNF. SWI/SNF
mediated chromatin-remodeling activity might facilitate tran-
scription factor binding and activate genes that inhibit cell cycle
progression (e.g., transcriptional activation of estrogen,
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glucocorticoid and RARs). hBRM associates with RB and E2F1
which blocks E2F1 activation function. The blocking of E2F1
activation causes the cell cycle arrest at G1 phase. Since RB
recruits HDACs, genes involved in cell cycle progression might
be repressed through synergestic action of SWI/SNF and HDACs.
Also mutations in hSNF5 gene  may impair its interaction with
hBRM. This may alter the function of SWI/SNF.
The SWI2/SNF2 family of DNA-dependent ATPases partici-
pates in a number of processes, including DNA repair, chroma-
tin remodeling, recombination and transcription. Individual
members of this family of proteins have been demonstrated to
interact with and regulate a limited set of transcription factors
including steroid receptors (estrogen receptor, androgen recep-
tor, etc.), p53, c-myc, the retinoblastoma10 protein and BRCA1.
Many of these factors have been investigated for their role in the
development and/or progression of breast cancer or prostate
cancer. Although the steroid receptor has been the primary
target for chemotherapy, an alternative target might be ATPase
catalytic site functionally coupled to a DNA binding site.
Phosphoaminoglycosides, a group of ATPase inhibitors, can
inhibit the activity of SWI2/SNF2 complex. Since, SWI2/SNF2
family members are involved in regulation of androgen receptor
function, inhibition of the ATP-dependent chromatin remodel-
ing activity selectively inhibits the growth of prostate cancer
cells. Regulation of the SWI2/SNF2 family members regulates a
limited number of transcription factors that are intimately in-
volved with cell growth and differentiation. SWI2/SNF2 pro-
teins could be novel targets for therapeutic exploitation with
specific interest in control of cell growth by phosphoamino-
glycosides.
Conclusion
Various concerted modifications of the histone tails and chro-
matin remodeling hold the key to gene regulation. Aberrant
gene expression may lead to disease condition. Thus the en-
zymes involved in chromatin remodeling are the crucial targets
10 Retinoblastoma  is a rare type
of eye cancer that develops in
the retina.  Although this disor-
der can occur at any age, it
usually develops in children.
Most cases of retinoblastoma
occur in only one eye, but both
eyes can be affected. The most
common sign of this disorder is
a visible whiteness in the nor-
mally black pupil (the part of
the eye that lets in light). Other
signs and symptoms of retino-
blastoma include crossed eyes
or eyes that do not point in the
same direction; persistent eye
pain, redness, or irritation; and
blindness or poor vision in the
affected eye.
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for therapy. By manipulating specific enzymes using modula-
tors (inhibitors and activators), a desired gene expression can be
achieved which could be very important in designing the thera-
peutics for a particular kind of chromatin associated disease.
This novel approach is called ‘Chromatin Therapy’ (Figure 3).
Much work though remains to be done in this area.
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Figure 3. Chromatin therapy.  In a disease state, normally active chromatin may be modified to a
repressed state and vice versa due to the events indicated. Specific modulators (e.g., inhibitors or
activators of HATs, inhibitors of HDACs and inhibitors of HMTase) could be useful to restore the
normal activities.
